The hubris and humility of cancer pharmacology in the post immuno‐oncology era
Abstract Cancer is a dreaded word, which has stimulated monumental efforts to discover and deliver effective cancer treatments for more than half a century. During the past two decades, our understanding of the molecular pathogenesis of cancer has increased remarkably. This has fostered an explosion...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-12-01
|
| Series: | Pharmacology Research & Perspectives |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/prp2.527 |
| _version_ | 1818595894473261056 |
|---|---|
| author | John S. Lazo |
| author_facet | John S. Lazo |
| author_sort | John S. Lazo |
| collection | DOAJ |
| description | Abstract Cancer is a dreaded word, which has stimulated monumental efforts to discover and deliver effective cancer treatments for more than half a century. During the past two decades, our understanding of the molecular pathogenesis of cancer has increased remarkably. This has fostered an explosion in the number of experimental agents and clinical trials coupled with a dramatic rise in the regulatory approval of therapies for human cancers. Unfortunately, our preclinical models perform poorly as predictive platforms for the ultimate success of clinical candidates, reflecting the complexity of cancer. Moreover the common combination of cancer drugs prescribes the need for a better understanding of the fundamental pharmacology of each agent. Here I briefly outline some of the fundamental changes that have and have not occurred in cancer pharmacology during the past two decades and prognosticate on possible future directions. |
| first_indexed | 2024-12-16T11:23:16Z |
| format | Article |
| id | doaj.art-07205dba2cac4265b5c38fce84609ce7 |
| institution | Directory Open Access Journal |
| issn | 2052-1707 |
| language | English |
| last_indexed | 2024-12-16T11:23:16Z |
| publishDate | 2019-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | Pharmacology Research & Perspectives |
| spelling | doaj.art-07205dba2cac4265b5c38fce84609ce72022-12-21T22:33:25ZengWileyPharmacology Research & Perspectives2052-17072019-12-0176n/an/a10.1002/prp2.527The hubris and humility of cancer pharmacology in the post immuno‐oncology eraJohn S. Lazo0Departments of Pharmacology and Chemistry University of Virginia Charlottesville VA USAAbstract Cancer is a dreaded word, which has stimulated monumental efforts to discover and deliver effective cancer treatments for more than half a century. During the past two decades, our understanding of the molecular pathogenesis of cancer has increased remarkably. This has fostered an explosion in the number of experimental agents and clinical trials coupled with a dramatic rise in the regulatory approval of therapies for human cancers. Unfortunately, our preclinical models perform poorly as predictive platforms for the ultimate success of clinical candidates, reflecting the complexity of cancer. Moreover the common combination of cancer drugs prescribes the need for a better understanding of the fundamental pharmacology of each agent. Here I briefly outline some of the fundamental changes that have and have not occurred in cancer pharmacology during the past two decades and prognosticate on possible future directions.https://doi.org/10.1002/prp2.527cancercancer cell linesdrug discoveryimmune therapypreclinical mouse models |
| spellingShingle | John S. Lazo The hubris and humility of cancer pharmacology in the post immuno‐oncology era Pharmacology Research & Perspectives cancer cancer cell lines drug discovery immune therapy preclinical mouse models |
| title | The hubris and humility of cancer pharmacology in the post immuno‐oncology era |
| title_full | The hubris and humility of cancer pharmacology in the post immuno‐oncology era |
| title_fullStr | The hubris and humility of cancer pharmacology in the post immuno‐oncology era |
| title_full_unstemmed | The hubris and humility of cancer pharmacology in the post immuno‐oncology era |
| title_short | The hubris and humility of cancer pharmacology in the post immuno‐oncology era |
| title_sort | hubris and humility of cancer pharmacology in the post immuno oncology era |
| topic | cancer cancer cell lines drug discovery immune therapy preclinical mouse models |
| url | https://doi.org/10.1002/prp2.527 |
| work_keys_str_mv | AT johnslazo thehubrisandhumilityofcancerpharmacologyinthepostimmunooncologyera AT johnslazo hubrisandhumilityofcancerpharmacologyinthepostimmunooncologyera |